Cemsidomide (CFT7455)
Relapsed/Refractory Multiple Myeloma
Key Facts
About C4 Therapeutics
C4 Therapeutics is a clinical-stage biotech company at the forefront of targeted protein degradation (TPD), a transformative therapeutic modality. Its mission is to design small-molecule degraders that offer a potentially superior approach to traditional inhibition by eliminating, not just inhibiting, disease-causing proteins. The company's strategy is built on its proprietary TORPEDO® platform, a hybrid business model combining internal oncology pipeline development with high-value strategic collaborations with pharmaceutical leaders like Roche and Biogen. Despite a challenging market valuation, C4T is progressing its lead assets, Cemsidomide and CFT8919, through clinical trials in hematologic and solid tumors.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Aplidin (plitidepsin) | PharmaMar | Approved (Conditional - AU) |
| CAR T-Cell Therapy Program | Dr. Reddy's Laboratories | Development |
| inobrodib + Pd (InoPd) | CellCentric | Phase 1/2 |
| TECVAYLI + DARZALEX FASPRO | Johnson and Johnson Innovative Medicine | Approved |
| HDP-101 | Heidelberg Pharma | Phase 1/2a |
| CT053 | CARsgen Therapeutics | Phase 1b/2 |
| P-BCMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| ABBV-383 | AbbVie | Phase 1 |
| Blenrep (belantamab mafodotin) | GSK plc | Phase III |
| bri-cel (BAY 2413334) | Bayer | Phase I |
| Ciltacabtagene autoleucel (Carvykti) | Genscript Biotech | Approved / Phase 3 |
| CAR-T Cell Therapy | Dr. Reddy's Laboratories | Discovery/Development |